Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera

Zentalis Pharmaceuticals, Inc.

Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.
Pays $30M upfront, milestone payment, and low single-digit royalty on Greater China net sales of azenosertib, ZN-d5, ZN-c5.
Sold its 40.3% equity stake in Zentera back to Zentera for de minimis consideration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.